Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
FIELD OF THE INVENTION
The present invention relates to compositions, methods of manufacture,
products and methods of use relating to films containing therapeutic actives.
The
invention more particularly relates to self-supporting dosage forms which
provide an
agonist acting alone or in combination with a buffer system to maximize
therapeutic
absorption of the agonist. Some embodiments also include an antagonist, with
the
buffer system acting to minimize the absorption of the antagonist. Such
compositions
are particularly useful for preventing misuse of the active while providing
sufficient
buccal adhesion of the dosage form.
BACKGROUND OF THE RELATED TECHNOLOGY
Oral administration of two therapeutic actives in a single dosage form can be
complex if the intention is to have one active absorbed into the body and the
other
active remain substantially unabsorbed. For example, one active may be
relatively
soluble in the mouth at one pH, and the other active may be relatively
insoluble at the
same pH. Moreover, the absorption kinetics of each therapeutic agent may be
substantially different due to differing absorption of the charged and
uncharged
species. These factors represent some of the challenges in appropriately co-
administering therapeutic agents.
Co-administration of therapeutic agents has many applications. Among such
areas of treatment include treating individuals who suffer from pain or other
medical
condition. Such individuals may have a tendency to suffer from serious
physical
dependence on the therapeutic agent, resulting in potentially dangerous
withdrawal
effects when the therapeutic agent is not administered to the individual. In
order to
provide treatment to patients, it is known to provide a reduced level of a
therapeutic
agent, which provides an effect of treating the condition, but does not
provide the
"high" that may be provided by the therapeutic agent. The drug provided may be
an
agonist or a partial agonist, which may provide a reduction in pain or other
symptom
that the patient is experiencing. However, even though these therapeutic
agents
provide only a low level of euphoric effect, they are capable of being abused
by the
individuals parenterally. In such cases, it is desirable to provide a
combination of the
therapeutic agent with a second therapeutic agent, which may decrease the
likelihood
1
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
of diversion and abuse of the first drug. For example, it is known to provide
a dosage
of an antagonist in combination with the agonist or partial agonist. The
narcotic
antagonist binds to a receptor in the brain to block the receptor, thus
reducing the
effect of the agonist.
One such combination of narcotic agents has been marketed under the trade
name Suboxone as an orally ingestible tablet. However, such combinations in
tablet
form have the potential for abuse. In some instances, the patient who has been
provided the drug may store the tablet in his mouth without swallowing the
tablet,
then later extract the agonist from the tablet and inject the drug into an
individual's
body. Although certain antagonists (such as highly water-soluble antagonists)
may be
used to help reduce the ability to separate the agonist, the potential for
abuse still
exists. Further, incorporation of an antagonist in combination with the pain-
relieving
agonist has been found to reduce side effects associated with administration
of the
agonist, such as constipation and other undesirable effects. It is desired to
provide a
dosage that cannot be easily removed from the mouth once it has been
administered.
There is currently a need for an orally dissolvable film dosage form that
provides the desired absorption levels of the agonist and antagonist, while
providing
an adhesive effect in the mouth, rendering it difficult to remove once placed
in the
mouth and achieving optimum absorption of the agonist while inhibiting
absorption of
the antagonist.
SUMMARY OF THE INVENTION
In one embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a polymeric carrier matrix; a
therapeutically effective amount of an agonist or a pharmaceutically
acceptable salt
thereof; and a buffer sufficient to maximize the absorption of the agonist.
In another embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a polymeric carrier matrix; a
therapeutically effective amount of an agonist or a pharmaceutically
acceptable salt
thereof; a therapeutically effective amount of an antagonist or a
pharmaceutically
acceptable salt thereof; and a buffering system; where the buffering system
possesses
a buffer capacity sufficient to inhibit the absorption of the antagonist
during the time
which the composition is in the oral cavity of a user.
2
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
In still another embodiment of the present invention, there is provided a
method of treatment, including the steps of: providing a film dosage
composition
including: a polymeric carrier matrix; a therapeutically effective amount of
an agonist
or a pharmaceutically acceptable salt thereof; and a buffer in an amount
sufficient to
maximize the absorption of the agonist; and administering the film dosage
composition to a patient.
In other embodiments of the present invention, there is provided a method of
treatment, including the steps of: providing a film dosage composition
including: a
polymeric carrier matrix; a therapeutically effective amount of an agonist or
a
pharmaceutically acceptable salt thereof; a therapeutically effective amount
of an
antagonist or a pharmaceutically acceptable salt thereof; a first buffer in an
amount
sufficient to obtain a local pH of the agonist of about 4 to about 9; a buffer
in an
amount sufficient to obtain a local pH of the antagonist of about 2 to about
4; and
administering the film dosage composition to a user.
In another embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a first region including: a
first
polymeric matrix; a therapeutically effective amount of an agonist or a
pharmaceutically acceptable salt thereof; and a first buffering system in an
amount
sufficient to optimize the absorption of the agonist; a second region
including: a
second polymeric matrix; a therapeutically effective amount of an antagonist;
and a
second buffering system in an amount sufficient to inhibit the absorption of
the
antagonist.
In a further embodiment of the present invention, there is provided an orally
dissolving film formulation including a first region including a
therapeutically
effective amount of an agonist and second region including a therapeutically
effective
amount of an antagonist, where the formulation provides an in vivo plasma
profile
having a Cmax of about 0.868-6.94 ng/ml for the agonist and an in vivo plasma
profile having a Cmax of about 32.5-260 pg/ml for the antagonist.
In another embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a polymeric carrier matrix; a
therapeutically effective amount of an agonist or a pharmaceutically
acceptable salt
thereof; a therapeutically effective amount of an antagonist or a
pharmaceutically
acceptable salt thereof; and a buffering system sufficient to obtain a local
pH of the
antagonist of about 2 to about 4.
3
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
In an embodiment of the present invention, there is provided a self-supporting
film dosage composition including: a polymeric carrier matrix; a
therapeutically
effective amount of an agonist or a pharmaceutically acceptable salt thereof;
a
therapeutically effective amount of an antagonist or a pharmaceutically
acceptable salt
thereof; and a buffering system sufficient to inhibit absorption of the
antagonist and
optimize absorption of the agonist when the film dosage composition is placed
in the
mouth of a user.
In another embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a first region including: a
first
polymeric matrix; a therapeutically effective amount of an agonist or a
pharmaceutically acceptable salt thereof; and a first buffering system in an
amount
sufficient to optimize absorption of the agonist when the film dosage
composition is
placed in the mouth of a user; and a second region including: a second
polymeric
matrix; a therapeutically effective amount of an antagonist; and a second
buffering
system in an amount sufficient to inhibit absorption of the antagonist when
the film
dosage composition is placed in the mouth of a user.
In yet another embodiment of the present invention, there is provided a
process of forming a film dosage composition including the steps of: casting a
film-
forming composition, the film-forming composition including: a polymeric
carrier
matrix; a therapeutically effective amount of an agonist or a pharmaceutically
acceptable salt thereof; a therapeutically effective amount of an antagonist
or a
pharmaceutically acceptable salt thereof; and a buffer in an amount sufficient
to
optimize absorption of the agonist and sufficient to inhibit absorption of the
antagonist when the film dosage composition is placed in the mouth of a user;
and
drying the film-forming composition to form a self-supporting film dosage
composition.
In still another embodiment of the present invention, there is provided a
method of treatment, including the steps of: providing a film dosage
composition
including: a polymeric carrier matrix; a therapeutically effective amount of
an agonist
or a pharmaceutically acceptable salt thereof; a therapeutically effective
amount of an
antagonist or a pharmaceutically acceptable salt thereof; and a buffering
system in an
amount sufficient to provide an in vivo plasma profile having a Cmax of about
0.624-
5.638 ng/ml for the agonist and an in vivo plasma profile having a Cmax of
less than
324 pg/ml for the antagonist; and administering the film dosage composition to
a user.
4
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
In another embodiment of the present invention, there is provided a self-
supporting film dosage composition including: a first region including: a
first
polymeric matrix; a therapeutically effective amount of an agonist or a
pharmaceutically acceptable salt thereof; and a first buffering system in an
amount
sufficient to optimize the absorption of the agonist; a second region
including: a
second polymeric matrix; a therapeutically effective amount of an antagonist;
and a
second buffering system in an amount sufficient to inhibit the absorption of
the
antagonist; where the second region dissolves at a faster rate when placed in
the oral
cavity of the user than the first region.
In another embodiment of the invention, there is provided a process of
forming a film dosage composition including the steps of: casting a first film-
forming
composition, the first film-forming composition including: a polymeric carrier
matrix;
a therapeutically effective amount of an agonist or a pharmaceutically
acceptable salt
thereof; and a buffer in an amount sufficient to optimize absorption of the
agonist
when the film dosage composition is placed in the mouth of a user; casting a
second
film-forming composition, the second film-forming composition including: a
polymeric carrier matrix; a therapeutically effective amount of an antagonist
or a
pharmaceutically acceptable salt thereof; and a buffer in an amount sufficient
to
inhibit absorption of the antagonist when the film dosage composition is
placed in the
mouth of a user; and laminating the first film-forming composition and the
second
film-forming composition together to form a self-supporting film dosage
composition.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Definitions
As used herein, the term Cmax refers to the mean maximum plasma
concentration after administration of the composition to a human subject. As
also
used herein, the term AUC refers to the mean area under the plasma
concentration-
time curve value after administration of the compositions formed herein. As
will be
set forth in more detail below, the term "optimizing the absorption" does not
necessarily refer to reaching the maximum absorption of the composition, and
rather
refers to reaching the optimum level of absorption at a given pH. The
"optimum"
absorption may be, for example, a level that provides a bioequivalent
absorption as
administration of the currently available Suboxone tablet. Thus, if a
bioequivalent
absorption to Suboxone is desired, the Cmax of buprenorphine may be about
0.67 to
5
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
about 5.36 ng/ml at dosages of from 2-16 mg buprenorphine at a given pH.
Similarly,
an "optimum" AUC of buprenorphine may be about 7.43 to about 59.46 hr*ng/ml at
dosages of from 2-16 mg buprenorphine at a given pH. As will be described in
more
detail below, it has been surprisingly discovered that the absorption of one
particular
agonist, buprenorphine, can provide an optimum absorption at a local pH of
about 3-4
as well as about 5.5-6.5. Thus, one may "optimize" the absorption of
buprenorphine
by providing a local pH of about 3-4 or about 5.5-6.5.
"Maximizing the absorption" refers to the maximum in vivo absorption values
achieved at a local pH of about 4 to about 9.
The term "local pH" refers to the local pH of the region of the carrier matrix
immediately surrounding the active agent as the matrix hydrates and/or
dissolves, for
example, in the mouth of the user.
By "inhibiting" the absorption of an active, it is meant achieving as complete
an ionization state of the active as possible, such that little to none of the
active is
measurably absorbable. For example, at a local pH of 3-3.5, the Cmax of an
active
such as naloxone for dosage of 0.5 mg to 4.0 mg ranges from 32.5 to 260 pg/ml,
and
an AUC of naloxone for dosage of 0.5 mg to 4.0 mg ranges from 90.55 to 724.4
hr*pg/ml. It is understood that at a local pH lower than 3.0, further
ionization would
be expected and thus result in lower absorption.
The term "bioequivalent" means obtaining 80% to 125% of the Cmax and
AUC values for a given active in a different product. For example, assuming
Cmax
and AUC values of buprenorphine for a commercially-available Suboxone0 tablet
(containing 2 mg buprenorphine and 0.5 mg naloxone) are 0.780 ng/ml and 6.789
hr*ng/ml, respectively, a bioequivalent product would have a Cmax of
buprenorphine
in the range of 0.624-0.975 ng/ml, and an AUC value of buprenorphine of 5.431-
8.486 hr*ng/ml.
It will be understood that the term "film" includes thin films, sheets and
wafers, in any shape, including rectangular, square, or other desired shape.
The films
described herein may be any desired thickness and size such that it may be
placed into
the oral cavity of the user. For example, the films may have a relatively thin
thickness
of from about 0.1 to about 10 mils, or they may have a somewhat thicker
thickness of
from about 10 to about 30 mils. For some films, the thickness may be even
larger,
i.e., greater than about 30 mils. Films may be in a single layer or they may
be multi-
layered, including laminated films.
6
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Oral dissolving films generally fall into three main classes: fast dissolving,
moderate dissolving and slow dissolving. Fast dissolving films generally
dissolve in
about 1 second to about 30 seconds in the mouth. Moderate dissolving films
generally dissolve in about 1 to about 30 minutes in the mouth, and slow
dissolving
films generally dissolve in more than 30 minutes in the mouth. Fast dissolving
films
may consist of low molecular weight hydrophilic polymers (i.e., polymers
having a
molecular weight between about 1,000 to 9,000, or polymers having a molecular
weight below 200,000). In contrast, slow dissolving films generally have high
molecular weight polymers (i.e., having a molecular weight in the millions).
Moderate dissolving films tend to fall in between the fast and slow dissolving
films. Moderate dissolving films dissolve rather quickly, but also have a good
level
of mucoadhesion. Moderate dissolving films are also flexible, quickly
wettable, and
are typically non-irritating to the user. For the instant invention, it is
preferable to use
films that fall between the categories of fast dissolving and moderate
dissolving.
Such moderate dissolving films provide a quick enough dissolution rate, most
desirably between about 1 minute and about 20 minutes, while providing an
acceptable mucoadhesion level such that the film is not easily removable once
it is
placed in the oral cavity of the user.
Inventive films described herein may include one or more agonists or partial
agonists. As used herein, the term "agonist" refers to a chemical substance
that is
capable of providing a physiological response or activity in the body of the
user. The
films described herein may further include one or more antagonists. As used
herein,
the term "antagonist" refers to any chemical substance that acts within the
body of the
user to reduce the physiological activity of another chemical substance. In
some
embodiments, an antagonist used herein may act to reduce and/or block the
physiological activity of the agonist. The actives may be water-soluble, or
they may
be water-insoluble. As used herein, the term "water-soluble" refers to
substances that
are at least partially dissolvable in a solvent, including but not limited to
water. The
term -water-soluble" does not necessarily mean that the substance is 100%
dissolvable in the solvent. The term "water-insoluble" refers to substances
that are
not readily dissolvable in a solvent, including but not limited to water.
Solvents may
include water, or alternatively may include other polar solvents by themselves
or in
combination with water.
Inventive Films
7
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
The present invention relates to methods of treating pain or other symptoms in
an individual while limiting the potential for abuse of the treatment. More
desirably,
the invention relates to the treatment of physical pain in an individual, for
example by
administration of an analgesic or other pain-relieving therapeutic agent. One
such
therapeutic agent that is known to treat pain in individuals includes an
agonist such as
buprenorphine. However, buprenorphine is known to be a partial agonist and
therefore can be abused, and as such it is desired to combine buprenorphine
with an
antagonist, thereby lessening the potential for abuse by parenteral injection.
Such
combination of drugs is currently provided via a product marketed under the
trade
name Suboxone0, which is an orally dissolvable tablet. This tablet which
provides a
combination of buprenorphine (an opioid agonist) and naloxone (an opioid
antagonist). However, even using an antagonist such as naloxone may be abused
by a
user. Therefore, the present invention provides a method of treating pain or
other
symptoms in a patient by providing an orally dissolvable film dosage, which
provides
a bioequivalent effect to Suboxone0. The film dosage further preferably
provides
buccal adhesion while it is in the user's mouth, rendering it difficult to
remove after
placement.
The film dosage composition preferably includes a polymeric carrier matrix.
Any desired polymeric carrier matrix may be used, provided that it is orally
dissolvable. Desirably, the dosage should have enough bioadhesion to not be
easily
removed and it should form a gel like structure when administered. The orally
consumable films are preferably moderate-dissolving in the oral cavity and
particularly suitable for delivery of actives, although both fast and
sustained release
compositions are also among the various embodiments contemplated. In some
embodiments, as will be described in more detail below, the inventive
combination
may include films that have more than one region, where each region has a
different
dissolution profile.
The films used in the pharmaceutical products may be produced by a
combination of at least one polymer and a solvent, optionally including other
fillers
known in the art. The solvent may be water, a polar organic solvent including,
but not
limited to, ethanol, isopropanol, acetone, or any combination thereof. In some
embodiments, the solvent may be a non-polar organic solvent, such as methylene
chloride. The film may be prepared by utilizing a selected casting or
deposition
method and a controlled drying process. For example, the film may be prepared
8
through controlled drying processes, which include application of heat and/or
radiation energy to the wet film matrix to form a visco-elastic structure,
thereby
controlling the uniformity of content of the film. Such processes are
described in
more detail in commonly assigned U.S. Patent No. 7,425,292. Alternatively, the
films
may be extruded as described in commonly assigned U.S. Application No.
10/856,176, filed on May 28, 2004, and published as U.S. Patent Publication
No.
2005/0037055 Al.
The polymer included in the films may be water-soluble, water-swellable,
water-insoluble, or a combination of one or more either water-soluble, water-
swellable or water-insoluble polymers. The polymer may include cellulose or a
cellulose derivative. Specific examples of useful water-soluble polymers
include, but
are not limited to, polyethylene oxide, pullulan, hydroxypropylmethyl
cellulose,
hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone,
earboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene
glycol,
xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic
acid,
methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and
combinations thereof. Specific examples of useful water-insoluble polymers
include,
but are not limited to, ethyl cellulose, hydroxypropyl ethyl cellulose,
cellulose acetate
phthalate, hydroxypropyl methyl cellulose phthalate and combinations thereof.
For
higher dosages, it may be desirable to incorporate a polymer which provides a
high
level of viscosity as compared to polymers suitable for lower dosages.
As used herein the phrase "water-soluble polymer" and variants thereof refer
to a polymer that is at least partially soluble in water, and desirably fully
or
predominantly soluble in water, or absorbs water. Polymers that absorb water
are
often referred to as being water-swellable polymers. The materials useful with
the
present invention may be water-soluble or water-swellable at room temperature
and
other temperatures, such as temperatures exceeding room temperature. Moreover,
the
materials may be water-soluble or water-swellable at pressures less than
atmospheric
pressure. Desirably, the water-soluble polymers are water-soluble or water-
swellable
having at least 20 percent by weight water uptake. Water-swellable polymers
having
a 25 or greater percent by weight water uptake are also useful. In some
embodiments,
films formed from such water-soluble polymers may be sufficiently water-
soluble to
be dissolvable upon contact with bodily fluids.
9
CA 2771089 2017-11-16
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Other polymers useful for incorporation into the films include biodegradable
polymers, copolymers, block polymers and combinations thereof. It is
understood
that the term -biodegradable" is intended to include materials that chemically
degrade
in the presence of a solvent, as opposed to materials that physically break
apart (i.e.,
bioerodable materials). Among the known useful polymers or polymer classes
which
meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid)
(PLA),
polydioxanes, polyoxalates, poly(a-esters), polyanhydrides, polyacetates,
polycaprolactones, poly(orthoesters), polyamino acids, polyaminocarbonates,
polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), and
mixtures
and copolymers thereof. Additional useful polymers include, stereopolymers of
L-
and D-lactic acid, copolymers of bis(p-carboxyphenoxy) propane acid and
sebacic
acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic
acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of
polyurethane
and (poly(lactic acid), copolymers of polyurethane and poly(lactic acid),
copolymers
of a-amino acids, copolymers of a-amino acids and caproic acid, copolymers of
a-
benzyl glutamate and polyethylene glycol, copolymers of succinate and
poly(glycols),
polyphosphazene, polyhydroxy-alkanoates and mixtures thereof. Binary and
ternary
systems are contemplated.
Other specific polymers useful include those marketed under the Medisorb and
Biodel trademarks. The Medisorb materials are marketed by the Dupont Company
of
Wilmington, Delaware and are generically identified as a "lactide/glycolide co-
polymer" containing "propanoic acid, 2-hydroxy-polymer with hydroxy-polymer
with
hydroxyacetic acid." Four such polymers include lactide/glycolide 100L,
believed to
be 100% lactide having a melting point within the range of 338 -347 F (170 -
175 C);
lactide/glycolide 100L, believed to be 100% glycolide having a melting point
within
the range of 437 -455 F (225 -235 C); lactide/glycolide 85/15, believed to be
85%
lactide and 15% glycolide with a melting point within the range of 338 -347 F
(170 -
175 C); and lactide/glycolide 50/50, believed to be a copolymer of 50%
lactide and
50% glycolide with a melting point within the range of 338 -347 F (170 -175
C).
The Biodel materials represent a family of various polyanhydrides which
differ chemically.
Although a variety of different polymers may be used, it is desired to select
polymers that provide mucoadhesive properties to the film, as well as a
desired
dissolution and/or disintegration rate. In particular, the time period for
which it is
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
desired to maintain the film in contact with the mucosal tissue depends on the
type of
active contained in the composition. Some actives may only require a few
minutes
for delivery through the mucosal tissue, whereas other actives may require up
to
several hours or even longer. Accordingly, in some embodiments, one or more
water-
.. soluble polymers, as described above, may be used to form the film. In
other
embodiments, however, it may be desirable to use combinations of water-soluble
polymers and polymers that are water-swellable, water- insoluble and/or
biodegradable, as provided above. The inclusion of one or more polymers that
are
water-swellable, water-insoluble and/or biodegradable may provide films with
slower
.. dissolution or disintegration rates than films formed from water-soluble
polymers
alone. As such, the film may adhere to the mucosal tissue for longer periods
or time,
such as up to several hours, which may be desirable for delivery of certain
active
components.
Desirably, the individual film dosage has a small size that is between about
.. 0.5-1 inch by about 0.5-1 inch. Most preferably, the film dosage is about
0.75 inches
x 0.5 inches. The film dosage should have good adhesion when placed in the
buccal
cavity or in the sublingual region of the user. Further, the film dosage
should disperse
and dissolve at a moderate rate, that is, between about 1 minute to about 30
minutes,
and most desirably between about 10 minutes and about 20 minutes. In some
embodiments, however, it may be desired to allow the individual film dosage to
dissolve slower, over a period of longer than about 30 minutes. In such slow
dissolving embodiments, it is preferable that the film dosage has strong
mucoadhesion
properties. In other embodiments, however, it may be desirable to use a faster
dissolving material, for example between about 1 to about 3 minutes. Further,
the
film dosage should include components that aid in adhesion to the inner
surface of the
user's oral cavity, such as the buccal cavity or sublingually. In particular,
for dual-
layered films, the region including the agonist should have a higher degree of
adhesion than the region including the antagonist. In this fashion, the
agonist may be
released quicker and ingested by the user.
For instance, in some embodiments, the films may include polyethylene oxide
alone or in combination with a second polymer component. In some embodiments,
the films may include polymers other than polyethylene oxide. The second
polymer
may be another water-soluble polymer, a water-swellable polymer, a water-
insoluble
polymer, a biodegradable polymer or any combination thereof. Suitable water-
soluble
11
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
polymers include, without limitation, any of those provided above. In some
embodiments, the water-soluble polymer may include hydrophilic cellulosic
polymers, such as hydroxypropyl cellulose and/or hydroxypropylmethyl
cellulose.
Other specific examples of useful water soluble polymers include, but are not
limited
to, polyethylene oxide (PEO), pullulan, hydroxypropyl cellulose, polydextrose,
polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium
alginate,
propylene glycol alginate, carrageenan, polyethylene glycol, xanthan gum,
tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid,
methylmethacrylate copolymer, poloxamer polymers, copolymers of acrylic acid
and
alkyl acrylate (availale as Pemulen0 polymers), carboxyvinyl copolymers,
starch,
gelatin, pectin, and combinations thereof.
Specific examples of useful water insoluble polymers include, but are not
limited to, ethyl cellulose, hydroxypropyl ethyl cellulose, cellulose acetate
phthalate,
hydroxypropyl methyl cellulose phthalate, acrylic polymers, vinyl acetate,
sodium
sulphonated polyesters, carboxylated acrylics, trimethylpentanediol/adipic
acid/glycerin cross polymer, polyglycerol-2-diisostearate/IPDI copolymer,
carboxylated vinyl acetate copolymer, vinylpyrrolicone/vinyl
acetate/alkylaminoacrylate terpolymers, vinylpyrrolidone/vinyl acetate
copolymer,
and combinations thereof.
In accordance with some embodiments, polyethylene oxide may range from
about 20% to 100% by weight in the polymer component, more specifically about
30% to about 70% by weight, and even more specifically about 40% to about 60%
by
weight. In some embodiments, one or more water-swellable, water-insoluble
and/or
biodegradable polymers also may be included in the polyethylene oxide-based
film.
Any of the water-swellable, water-insoluble or biodegradable polymers provided
above may be employed. The second polymer component may be employed in
amounts of about 0% to about 80% by weight in the polymer component, more
specifically about 30% to about 70% by weight, and even more specifically
about
40% to about 60% by weight.
The molecular weight of the polyethylene oxide also may be varied. In some
embodiments, high molecular weight polyethylene oxide, such as about 4
million,
may be desired to increase mucoadhesivity of the film. In some other
embodiments,
the molecular weight may range from about 100,000 to 900,000, more
specifically
from about 100,000 to 600,000, and even more specifically from about 100,000
to
12
300,000. In some embodiments, it may be desirable to combine high molecular
weight (600,000 to 900,000) with low molecular weight (100,000 to 300,000)
polyethylene oxide in the polymer component. Suitable polymers include those
described in the applicant's co-pending application, U.S. Publication Number
2008-
0260809.
A variety of optional components and fillers also may be added to the films.
These may include, without limitation: surfactants; plasticizers;
polyalcohols; anti-
foam ing agents, such as silicone-containing compounds, which promote a
smoother
film surface by releasing oxygen from the film; thermo-setting gels such as
pectin,
carageenan, and gelatin, which help in maintaining the dispersion of
components;
inclusion compounds, such as cyciodextrins and caged molecules; coloring
agents;
and flavors. In some embodiments, more than one active components may be
included in the film.
Additives may be included in the films. Examples of classes of additives
include excipients, lubricants, buffering agents, stabilizers, blowing agents,
pigments,
coloring agents, fillers, bulking agents, sweetening agents, flavoring agents,
fragrances, release modifiers, adjuvants, plasticizers, flow accelerators,
mold release
agents, polyols, granulating agents, diluents, binders, buffers, absorbents,
glidants,
adhesives, anti-adherents, acidulants, softeners, resins, demulcents,
solvents,
surfactants, emulsifiers, elastomers and mixtures thereof. These additives may
be
added with the active ingredient(s).
Useful additives include, for example, gelatin, vegetable proteins such as
sunflower protein, soybean proteins, cotton seed proteins, peanut proteins,
grape seed
proteins, whey proteins, whey protein isolates, blood proteins, egg proteins,
acrylated
proteins, water-soluble polysaccharides such as alginates, carrageenans, guar
gum,
agar-agar, xanthan gum, gellan gum, gum arabic and related gums (gum ghatti,
gum
karaya, gum tragancanth), pectin, water-soluble derivatives of cellulose:
alkylcelluloses hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such
as
methylcelulose, hydroxymethylcellulose, hydroxyethylcellulose,
hydroxypropylcellulose, hydroxyethylmethylcellulose,
hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters
and
hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP),
hydroxypropylmethylcellulose (HPMC); carboxyalkylcelluloses,
carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as
13
CA 2771089 2017-11-16
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
carboxymethylcellulose and their alkali metal salts; water-soluble synthetic
polymers
such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids
and
polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols,
polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), PVY/vinyl
acetate
copolymer, and polycrotonic acids; also suitable are phthalated gelatin,
gelatin
succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of
starch,
cationically modified acrylates and methacrylates possessing, for example, a
tertiary
or quaternary amino group, such as the diethylaminoethyl group, which may be
quaternized if desired; and other similar polymers.
Such extenders may optionally be added in any desired amount desirably
within the range of up to about 80%, desirably about 3% to 50% and more
desirably
within the range of 3% to 20% based on the weight of all film components.
Further additives may be flow agents and opacifiers, such as the oxides of
magnesium aluminum, silicon, titanium, etc. desirably in a concentration range
of
about 0.02% to about 3% by weight and desirably about 0.02% to about 1% based
on
the weight of all film components.
Further examples of additives are plasticizers which include polyalkylene
oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-
propylene
glycols, organic plasticizers with low molecular weights, such as glycerol,
glycerol
monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol,
propylene
glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl
citrate, and the
like, added in concentrations ranging from about 0.5% to about 30%, and
desirably
ranging from about 0.5% to about 20% based on the weight of the polymer.
There may further be added compounds to improve the texture properties of
the starch material such as animal or vegetable fats, desirably in their
hydrogenated
form, especially those which are solid at room temperature. These fats
desirably have
a melting point of 50 C or higher. Preferred are tri-glycerides with C12-, C14-
9 C16-9
C18-, Cm- and C22- fatty acids. These fats can be added alone without adding
extenders or plasticizers and can be advantageously added alone or together
with
mono- and/or di-glycerides or phosphatides, especially lecithin. The mono- and
di-
glycerides arc desirably derived from the types of fats described above, i.e.
with C12-9
C14-, C16-, C18-, C20- and C22- fatty acids.
14
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
The total amounts used of the fats, mono-, di-glycerides and/or lecithins may
be up to about 5% and preferably within the range of about 0.5% to about 2% by
weight of the total film composition.
It further may be useful to add silicon dioxide, calcium silicate, or titanium
dioxide in a concentration of about 0.02% to about 1% by weight of the total
composition. These compounds act as flow agents and opacifiers.
Lecithin is one surface active agent for use in the films described herein.
Lecithin may be included in the feedstock in an amount of from about 0.25% to
about
2.00% by weight. Other surface active agents, i.e. surfactants, include, but
are not
limited to, cetyl alcohol, sodium lauryl sulfate, the SpansTM and TweensTm
which are
commercially available from ICI Americas, Inc. Ethoxylated oils, including
ethoxylated castor oils, such as Cremophor0 EL which is commercially available
from BASF, are also useful. CarbowaxTM is yet another modifier which is very
useful
in the present invention. TweensTm or combinations of surface active agents
may be
used to achieve the desired hydrophilic-lipophilic balance ("HLB").
Other ingredients include binders which contribute to the ease of formation
and general quality of the films. Non-limiting examples of binders include
starches,
pregelatinize starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium
carboxymethyl cellulose, ethylcellulose, polyacrylami des, polyvinyloxoazoli
done, and
polyvinylalcohols. If desired, the film may include other additives, such as
keratin, or
proteins, including proteins that are useful in forming a gel, such as
gelatine.
Further potential additives include solubility enhancing agents, such as
substances that form inclusion compounds with active components. Such agents
may
be useful in improving the properties of very insoluble and/or unstable
actives. In
.. general, these substances are doughnut-shaped molecules with hydrophobic
internal
cavities and hydrophilic exteriors. Insoluble and/or instable actives may fit
within the
hydrophobic cavity, thereby producing an inclusion complex, which is soluble
in
water. Accordingly, the formation of the inclusion complex permits very
insoluble
and/or instable actives to be dissolved in water. A particularly desirable
example of
such agents are cyclodextrins, which are cyclic carbohydrates derived from
starch.
Other similar substances, however, are considered well within the scope of the
present
invention.
Suitable coloring agents include food, drug and cosmetic colors (FD&C), drug
and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C).
These
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
colors arc dyes, their corresponding lakes, and certain natural and derived
colorants.
Lakes are dyes absorbed on aluminum hydroxide.
Other examples of coloring agents include known azo dyes, organic or
inorganic pigments, or coloring agents of natural origin. Inorganic pigments
are
preferred, such as the oxides or iron or titanium, these oxides, being added
in
concentrations ranging from about 0.001 to about 10%, and preferably about 0.5
to
about 3%, based on the weight of all the components.
Flavors may be chosen from natural and synthetic flavoring liquids. An
illustrative list of such agents includes volatile oils, synthetic flavor
oils, flavoring
aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves,
flowers,
fruits, stems and combinations thereof A non-limiting representative list of
examples
includes mint oils, cocoa, and citrus oils such as lemon, orange, grape, lime
and
grapefruit and fruit essences including apple, pear, peach, grape, strawberry,
raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
Other useful flavorings include aldehydes and esters such as benzaldehyde
(cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-
citral (lemon,
lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9
(citrus
fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-
dimethyloctanol (green fruit), and 2-dodecen al (citrus, mandarin),
combinations
thereof and the like.
The sweeteners may be chosen from the following non-limiting list: glucose
(corn syrup), dextrose, invert sugar, fructose, and combinations thereof
saccharin and
its various salts such as the sodium salt; dipeptide sweeteners such as
aspartame;
dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside);
chloro
derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol,
mannitol,
xylitol, and the like. Also contemplated are hydrogenated starch hydrolysates
and the
synthetic sweetener 3,6-dihydro-6-methy1-1-1-1,2,3-oxathiazin-4-one-2,2-
dioxide,
particularly the potassium salt (acesulfame-K), and sodium and calcium salts
thereof,
and natural intensive sweeteners, such as Lo Han Kuo. Other sweeteners may
also be
used.
The films may include one or more additives to provide a taste masking of the
active component. For example, the films may include ionic exchange resins,
including but not limited to a water-insoluble organic or inorganic matrix
material
having covalently bound functional groups that are ionic or capable of being
ionized
16
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
under appropriate conditions. The organic matrix may be synthetic (e.g.,
polymers or
copolymers or acrylic acid, methacrylic acid, sulfonated styrene or sulfonated
divinylbenzene) or partially synthetic (e.g., modified cellulose or dextrans).
The
inorganic matrix may be, for example, silica gel modified by the addition of
ionic
groups. Most ion exchange resins are cross-linked by a crosslinking agent,
such as
divinylbenzene.
Anti-foaming and/or de-foaming components may also be used with the films.
These components aid in the removal of air, such as entrapped air, from the
film-
forming compositions. Such entrapped air may lead to non-uniform films.
Simethicone is one particularly useful anti-foaming and/or de-foaming agent.
The
present invention, however, is not so limited and other anti-foam and/or de-
foaming
agents may suitable be used.
As a related matter, simethicone and related agents may be employed for
densification purposes. More specifically, such agents may facilitate the
removal of
voids, air, moisture, and similar undesired components, thereby providing
denser, and
thus more uniform films. Agents or components which perform this function can
be
referred to as densification or densifying agents. As described above,
entrapped air
or undesired components may lead to non-uniform films.
Simethicone is generally used in the medical field as a treatment for gas or
colic in babies. Simethicone is a mixture of fully methylated linear siloxane
polymers
containing repeating units of polydimethylsiloxane which is stabilized with
trimethylsiloxy end-blocking unites, and silicon dioxide. It usually contains
90.5-
99% polymethylsiloxane and 4-7% silicon dioxide. The mixture is a gray,
translucent, viscous fluid which is insoluble in water.
When dispersed in water, simethicone will spread across the surface, forming
a thin film of low surface tension. In this way, simethicone reduces the
surface
tension of bubbles air located in the solution, such as foam bubbles, causing
their
collapse. The function of simethicone mimics the dual action of oil and
alcohol in
water. For example, in an oily solution any trapped air bubbles will ascend to
the
surface and dissipate more quickly and easily, because an oily liquid has a
lighter
density compared to a water solution. On the other hand, an alcohol/water
mixture is
known to lower water density as well as lower the water's surface tension. So,
any air
bubbles trapped inside this mixture solution will also be easily dissipated.
Simethicone solution provides both of these advantages. It lowers the surface
energy
17
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
of any air bubbles that trapped inside the aqueous solution, as well as
lowering the
surface tension of the aqueous solution. As the result of this unique
functionality, simethicone has an excellent anti-foaming property that can be
used for
physiological processes (anti-gas in stomach) as well as any for external
processes
that require the removal of air bubbles from a product.
In order to prevent the formation of air bubbles in the films, the mixing step
may be performed under vacuum. However, as soon as the mixing step is
completed,
and the film solution is returned to the normal atmosphere condition, air will
be re-
introduced into or contacted with the mixture. In many cases, tiny air bubbles
will be
.. again trapped inside this polymeric viscous solution. The incorporation of
simethicone into the film-forming composition either substantially reduces or
eliminates the formation of air bubbles during and after mixing.
Simethicone may be added to the film-forming mixture as an anti-foaming
agent in an amount from about 0.01 weight percent to about 5.0 weight percent,
more
desirably from about 0. 05 weight percent to about 2.5 weight percent, and
most
desirably from about 0. 1 weight percent to about 1.0 weight percent.
Any other optional components described in commonly assigned U.S. Patent
No. 7,425,292 and U.S. Application No. 10/856,176, referred to above, also may
be
included in the films described herein.
When the dosage form includes at least one antagonist in addition to the
agonist, it may be desired to control the release of the antagonist, so as to
minimize or
wholly prevent the absorption of the antagonist from the dosage form when
taken
orally. In this fashion, the antagonist may be released faster and a larger
proportion of
it may be present as the ionized form in solution, thereby lessening the
likelihood of
its absorption in the body. Desirably, the dosage form is a self-supporting
film
composition, which is placed into the oral cavity of the user. In a dosage
form that is
to be placed in the oral cavity, it is desired to absorb the agonist buccally,
so as to
provide rapid absorption of the agonist into the body of the user. At the same
time, it
may be desired to inhibit or reduce absorption of any antagonist buccally,
thereby
allowing the antagonist to be swallowed and destroyed in the stomach, or in
some
cases absorbed in the colon. Inhibiting the absorption of an antagonist may
alternatively be achieved via physical means, such as by encapsulating the
antagonist
in a material that blocks absorption. It is desired, however, to reduce the
absorption
18
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
of the antagonist by chemical means, such as by controlling the local pH of
the dosage
form.
It has been found that by controlling the local pH of the dosage form, the
release and/or absorption of the actives therein may be controlled. For
example, in a
dosage that includes an amount of an agonist, the local pH may be controlled
to a
level that optimizes its release and/or absorption into the oral cavity of the
user. In
dosages incorporating an amount of an agonist and an amount of an antagonist,
the
local pH may be controlled to a level that maximizes the release and/or oral
absorption of the agonist while simultaneously minimizing the release and/or
oral
absorption of the antagonist. For example, the film dosage may include
distinct
regions, one region including an agonist and the other region including an
antagonist,
where the local pH of each region is optimized for the desired effect.
The dosage form preferably includes a combination of an agonist and an
antagonist, while the dosage has a controlled local pH. It should be
understood that
the present invention is not limited to the use of any one particular agonist
and/or
antagonist, and any agonist (or partial agonist) and any antagonist may be
incorporated into the present invention. The agonist and optional antagonist
should
be selected from those agonists and antagonists that are useful in treating
the
particular symptom being treated. The inventive films discussed herein are
best
suited for agonists and/or antagonists that are basic in nature. Suitable
agonists
(and/or partial agonists) may include buprenorphine (pKa = 8.42), sufentanil
(pKa =
8.0), morphine (pKa = 8.0), fentanil (pKa = 8.4), alfentanil (pKa = 6.5),
pethidine
(pKa = 8.7), apomorphine (pKa = 8.9), alphaprodine (pKa = 8.7), remifentanil
(pKa =
7.0), methadone (pKa = 9.2), codeine (pKa = 8.2), dihydrocodeine (pKa = 9.4),
morphine (pKa = 8.0), oxycodone (pKa = 8.53), oxymorphone (pKa = 8.17),
tramadol
(pKa = 9.41), or pharmaceutically acceptable salts thereof. Suitable
antagonists
(and/or partial antagonists) may include naloxone, naltrexone, nalorphine and
levallorphan, or therapeutically acceptable salts thereof.
As discussed above, the local pH of the dosage is preferably controlled to
provide the desired release and/or absorption of the agonist and antagonist.
Suitable
agonists may have a pKa of about 5 to about 9.5, and most preferably from
about 8.0
to about 9Ø Suitable antagonists may have a pKa of about 6.0 to about 9.0,
and most
preferably about 7.0 to about 9Ø For example, naloxone has a pKa of about
7.94.
19
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
According to pH partition theory, one would expect that saliva (which has a
local pH of about 6.5) would maximize the absorption of both actives. As
generally
understood, absorption of an active depends on the available unionized form of
the
active. Thus, as the local pH of the surrounding environment is lowered, basic
actives
will be more ionized, and less will be available for absorption. For an active
which
has a pKa of about 8, one would expect a higher level of absorption to occur
at a local
pH level of about 6.5, whereas a lower level of absorption should occur at a
local pH
of about 3.5, since most of the active would be ionized. As will be described
in more
detail in the Examples below, controlling the local pH of the film
compositions of the
present invention provides a system in which the desired release and/or
absorption of
the components is achieved.
In one embodiment, the dosage form is a self-supporting film. In this
embodiment, the film dosage includes a polymer carrier matrix, a
therapeutically
effective amount of an agonist or a pharmaceutically acceptable salt thereof,
and a
buffer. Preferably, the agonist is a partial agonist, and most desirably the
agonist is an
opioid agonist, such as buprenorphine. The buffer is preferably capable of
providing
a local pH of the composition within a range that provides a controllable
level and
desirably an optimal treatment level of absorption of the agonist. For
example, it may
be desired to provide an absorption of buprenorphine that is bioequivalent to
a
Suboxone tablet.
It has been surprisingly discovered by the Applicants that certain agonists,
such as buprenorphine, are capable of being suitably absorbed when the local
pH of
the film composition is either between about 3 to about 4 or between about 5
to about
9. Thus, the local pH for the film including the agonist may be either from
about 3 to
about 4 or from about 5 to about 9. To provide a maximum absorption of
buprenorphine, for example, the local pH of the film composition may be about
5.5.
To provide an absorption of buprenorphine that is bioequivalent to the
Suboxone0
tablet, the local pH of the film composition may be about 6 to about 7. The
resulting
dosage is a film composition that allows for a rapid and effective release of
the
agonist (such as buprenorphine) into the oral cavity of the user. At the same
time, the
film composition desirably has a sufficient adhesion profile, such that the
film cannot
easily be removed, or cannot be removed at all, from the oral cavity of the
user once it
has been placed into the cavity. Full release of the agonist may take place
within less
than about thirty minutes, e.g., within about 10 minutes to about 30 minutes
and
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
preferably remains in the oral cavity for at least 1 minute and desirably
about 1 to
about 30 minutes.
It may be desirable to combine the opioid agonist (or partial agonist) in the
film composition with an opioid antagonist or a pharmaceutically acceptable
salt
thereof. The agonist and antagonist may be dispersed throughout the dosage
separately or the agonist and antagonist may be separately dispersed in
individual film
regions. Most desirably the antagonist includes naloxone, but any suitable
antagonist
may be selected as desired. The antagonist may optionally be water-soluble, so
as to
render separation of the antagonist and agonist difficult, thereby lessening
the
potential for diversion abuse of the agonist.
As with a film including an agonist, a film including an agonist and an
antagonist is desirably pH-controlled through the inclusion of a buffer. At
the desired
local pH level of the agonist and the antagonist, optimal absorption of the
agonist may
be achieved while the absorption of the antagonist may be greatly inhibited.
The film may contain any desired level of self-supporting film forming
polymer, such that a self-supporting film composition is provided. In one
embodiment, the film composition contains a film forming polymer in an amount
of at
least 25% by weight of the composition. The film forming polymer may
alternatively
be present in an amount of at least 50% by weight of the composition, and
desirably
in a range of about 25% to about 75%, and most desirably from about 30% to
about
50% by weight of the composition. As explained above, any film forming
polymers
may be used as desired.
Any desired level of agonist and optional antagonist may be included in the
dosage, so as to provide the desired therapeutic effect. In one particular
embodiment,
the film composition includes about 2 mg to about 16 mg of agonist per dosage.
More desirably, the film composition includes about 4 mg to about 12 mg of
agonist
per dosage. If desired, the film composition may include about 0.5 mg to about
5 mg
of antagonist per dosage. More desirably, the film composition includes about
1 mg
to about 3 mg of antagonist per dosage. If an antagonist is incorporated into
the film,
the film composition may include the antagonist in a ratio of about 6:1 ¨ 2:1
agonist
to antagonist. Most desirably, the film composition contains about 4:1 agonist
to
antagonist per dosage. For example, in one embodiment, the dosage includes an
agonist in an amount of about 12 mg, and includes an antagonist in an amount
of
about 3 mg.
21
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
The film compositions further desirably include at least one buffer so as to
control the local pH of the film composition. Any desired level of buffer may
be
incorporated into the film composition so as to provide the desired local pH
level.
The buffer is preferably provided in an amount sufficient to control the
release from
.. the film and/or the absorption into the body of the agonist and the
optional antagonist.
In a desired embodiment, the film composition includes buffer in a ratio of
buffer to
agonist in an amount of from about 2:1 to about 1:5 (buffer:agonist). The
buffer may
alternatively be provided in a 1:1 ratio of buffer to agonist. A film
composition
including an antagonist preferably has a local pH of about 2 to about 4. Any
buffer
.. may be used as desired. In some embodiments, the buffer may include sodium
citrate,
citric acid, succinic acid, malic acid, phosphoric acid, boric acid, and
combinations
thereof. The buffer may include a buffering system including a combination of
components, such as Citric Acid/Sodium Citrate, Succinic Acid/Monosodium
Succinate, Glycine/SodiumGlycine, Malic Acid/Sodium Malate, Phosphoric
Acid/Sodium Phosphate, Fumaric Acid/Sodium Fumarate, Monosodium
Phosphate/Disodium Phosphate, and Boric Acid/Sodium Borate.
In this embodiment, the resulting film composition includes a polymer matrix,
an agonist, and an optional antagonist, while the film composition has a
controlled
local pH to the level desired. The buffer is desirably present in an amount to
provide
a therapeutically adequate absorption of the agonist, while simultaneously
limiting or
preventing substantial absorption of the antagonist. Controlling of the local
pH
allows for the desired release and/or absorption of the components, and thus
provides
a more useful and effective dosage.
The film dosage composition may include a polymer carrier matrix, a
therapeutically effective amount of agonist, a therapeutically effective
amount of
antagonist, and a buffering system. A "therapeutically effective amount" of an
antagonist is intended to refer to an amount of the antagonist that is useful
in diverting
abuse of the agonist by a user. The buffering system may include a buffer in
addition
to a solvent. The buffering system desirably includes a sufficient level of
buffer so as
to provide a desired local pH level of the film dosage composition.
In addition to a desired local pH level, the buffer desirably has a buffer
capacity sufficient to maintain ionization of the optional antagonist during
the time
that the composition is in the oral cavity of a user. Maintaining ionization
of the
antagonist serves to limit the absorption of the antagonist, and thus provide
the
22
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
desired control of the antagonist. While the ionization of the antagonist is
limited, the
ionization of the agonist may not be so limited. As such, the resulting dosage
form
provides absorption of the agonist to the user, while sufficiently reducing
and/or
preventing absorption of the antagonist.
In other embodiments, the film dosage composition of the present invention
may include an agonist in a sufficient amount so as to provide a release
profile
bioequivalent to a tablet containing a higher amount of the agonist. By
providing a
film dosage composition with an agonist and simultaneously controlling the
local pH
of the film dosage composition, an effective release and absorption of the
agonist may
be achieved with less of the agonist present in the dosage. For example, the
film
dosage composition may include an agonist in an amount that is at least 1.5
times less
than the amount of the agonist required in a tablet, but still provides a
bioequivalent
release profile. In some embodiments, the agonist may be a partial agonist. In
some
embodiments the agonist may be an opioid agonist. In desired embodiments, the
agonist includes buprenorphine or a pharmaceutically acceptable salt thereof.
The film dosage composition including an agonist, may be configured to
provide an in vivo plasma profile having a mean maximum plasma concentration
(Cmax) in a desired range. For example, the desired Cmax may be a
bioequivalent
level to that of a Suboxone tablet. It has been discovered by the Applicants
that
controlling the Cmax of the film composition allows one to control the
absorption of
the active (such as an agonist) into the user. The resulting film composition
is more
effective and suitable for delivery to a user.
In one embodiment, the Cmax of the film composition may be about 6.4 ng/ml
or less. If desired, the Cmax of the film composition may be less than about
5.2
ng/ml, less than about 3.8 ng/ml, less than about 1.9 ng/ml, or less than
about 1.1
ng/ml, depending on the desired dosage level. In such embodiments, the agonist
may
be present in an amount of from about 2 mg to about 16 mg per dosage, or, if
desired
about 4 mg to about 12 mg per dosage. The agonist may include buprenorphine or
a
pharmaceutically acceptable salt thereof.
It has further been discovered that, by controlling the mean area under the
curve (AUC) value of the film composition, a more effective dosage form may be
provided. In one embodiment, the film composition may include a mean AUC value
of about 6.8 hr.ng/ml or greater. Alternatively, the film composition may
include a
mean AUCinf value of from about 6.8 hr.ng/ml to about 66 hr.ng/ml.
23
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
As explained above, the film compositions may include an optional antagonist.
When the film composition includes a combination of agonist and antagonist,
the film
composition may be configured to provide a particular Cmax and/or AUC for the
antagonist. For example, when a buprenorphine agonist and a naloxone
antagonist are
incorporated into the film composition, the naloxone may be configured to
provide a
Cmax of less than about 400 pg/ml, less than about 318 pg/ml, less than about
235
pg/ml, less than about 92 pg/ml or less than about 64 pg/ml. In such films,
the
naloxone may provide a mean AUC value of less than about 1030 hr.ng/ml.
In formulations which include an agonist in combination with an antagonist,
the film composition may be prepared to provide a desired Cmax and/or AUC
value
for each of the agonist and antagonist. For example, a dosage having 16 mg of
agonist and 4 mg of antagonist may provide an in vivo plasma profile having a
Cmax
of less than about 6.4 ng/ml for the agonist and an in vivo plasma profile
having a
Cmax of less than about 400 pg/ml for the antagonist. Such formulation may
also
provide an AUC value of more than about 6.8 hr.ng/m1 for the agonist. If
desired, the
formulation may provide an AUCinf value of less than about 1030 hr.pg/m1 for
the
antagonist. Bioequivalence levels are set forth in more detail in the Examples
discussed below. Such compositions may include the agonist and the antagonist
in
any desired amount, and in a preferred embodiment, the composition includes
about 2
.. mg to about 16 mg of the agonist per dosage and about 0.5 mg to about 4 mg
of the
antagonist per dosage. Most desirably, the agonist and antagonist are present
in
amounts of about 4:1 by weight agonist to antagonist.
In one particular embodiment, there may be provided a self-supporting film
dosage composition including more than one region (referred to as a "dual-film
product" or a "dual-region product"). The multiple regions may be disposed on
top of
each other, to the side of each other, or disposed internally of each other.
For
example, the dosage composition may include two separate regions, disposed in
such
a configuration where the first region is on top of the second region, or vice
versa. If
desired, the two regions may be laminated to each other so as to provide a
single
dosage form. In such embodiments, the first region may be dried prior to
laminating
any additional regions thereto. Similarly, the second region may be dried
prior to
laminating the first region thereto. Alternatively, either the first or second
region may
be at least partially dried prior to laminating any additional regions
thereto.
24
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
In such multi-region embodiments, there is provided a first region, which
includes a first polymeric matrix and a therapeutically effective amount of an
agonist.
The agonist may be a partial agonist, and the agonist may be an opioid
agonist. One
such opioid agonist includes buprenorphine, but any desired agonist may be
used to
treat the particular symptom desired. The first region desirably includes a
first
buffering system in an amount sufficient to provide a local pH of the agonist
so as to
optimize the release and/or absorption of the agonist. The first region may be
in
communication with a second region. The second region may include a second
polymeric matrix and a therapeutically effective amount of an antagonist. One
such
antagonist includes naloxone, but any desired antagonist may be used as
desired. The
second region may further include a second buffering system in an amount
sufficient
to provide a local pH of the antagonist so as to inhibit the absorption of the
antagonist.
In some embodiments, it may be desirable to have one region be dissolved at a
faster
rate than the second region when it is placed into the mouth of the user. For
example,
it may be desired to have the region including an antagonist dissolve at a
faster rate
than the region including an agonist, or vice versa.
In such multi-region film dosages, the first and second regions may work in
cooperation to provide a desired absorption profile of the agonist and the
antagonist.
For example, the first buffering system may be present in an amount sufficient
to
provide increased absorption of the agonist, while the second buffering system
is
present in an amount sufficient to provide a decreased absorption of the
antagonist. In
some embodiments, the first buffering system may be present in an amount
sufficient
to provide a local pH of the first region so as to provide an optimum
absorption of the
agonist, i.e., of from either about 3 to about 4 or of from about 4 to about
9, and more
specifically from about 6 to about 9. In some embodiments, the second
buffering
system may be present in an amount sufficient to provide a local pH of the
second
region of from about 2 to about 4, and more specifically about 2 to about 3.
For a
multi-region film dosage including buprenorphine in the first region and
naloxone in
the second region, the local pH of the buprenorphine region is desirably
either from
about 3 to about 4 or from about 5.5 to about 6.5, and the local pH of the
naloxone
region is about 2.0 to about 3Ø
Depending on the particular agonist and antagonist incorporated in the dosage,
the desired local pH level for each region may be greater or lower so as to
optimize
absorption of the agonist while inhibiting absorption of the antagonist.
Generally, the
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
local pH of the agonist-containing region is desirably between about 4 to
about 9, and
most desirably about 6 to about 9. The local pH for the antagonist-containing
region
is most desirably about 2 to about 4. Again, however, it will be understood
that the
particular agonist incorporated into the dosage may be more optimally absorbed
at a
higher or lower pH.
The first and second buffering systems may be the same or they may be
different. Additionally, the first polymeric matrix and the second polymeric
matrix
may be the same or they may be different. Any desired levels of agonist and
antagonist may be provided, and desirably the dosage composition includes
about 2
mg to about 16 mg of the agonist and about 0.5 mg to about 4 mg of the
antagonist
per dosage unit. More desirably, the dosage composition includes about 4 mg to
about 12 mg of the agonist and about 1 mg to about 3 mg of the antagonist per
dosage
unit.
The first and second regions may be formed together in any desired means. In
one embodiment, the second region may be coated, sprayed, or placed onto at
least
one surface of the first region. Alternatively, the first and second regions
may be co-
extruded. In some embodiments, the first and second regions may be laminated
to
each other by means of a suitable composition. Further, the first region may
be
formed first, and then subsequently dipped into a solution of a wet
composition,
which is then allowed to dry and form the second region. As will be understood
by
one of ordinary skill in the art, the first region may include the antagonist
while the
second region includes the agonist. Further, both regions may include a
desired
amount of agonist and antagonist so as to provide a desired release and
absorption.
The first region may include more components by weight than the second
region, or vice versa. For example, the first region may have a total weight
that is
more than the total weight of the second region, or vice versa. Alternatively,
the first
and second regions may include the same amount of components by weight.
In another embodiment, there may be provided a self-supporting film dosage
composition having more than one region, where each region includes a
polymeric
matrix and a water-soluble and/or a water-insoluble active. The dosage
composition
preferably includes a therapeutically effective amount of a water-soluble
active and a
therapeutically effective amount of water-insoluble active. Each region
preferably
includes a buffer in an amount sufficient to control the absorption profiles
of the
water-soluble and water-insoluble actives in each region, depending on the
desired
26
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
level of absorption of the active desired. In one desired embodiment, a first
buffer is
present in the first region in an amount sufficient to obtain a local pH of
one region of
about 2 to about 4, while a second buffer is present in the second region in
an amount
sufficient to obtain a local pH of the second region of about 4 to about 9.
The present invention provides a method of treating various problems in a
patient, including, for example physical pain experienced by a patient.
Desirably, the
patient is treated by providing a dosage to the patient, which provides an
effective
release of therapeutic active but simultaneously provides a suitable adhesion
so that
the dosage cannot be easily removed. The dosage forms provided herein are
particularly useful in preventing diversion of a drug. In one method of
treatment, an
orally dissolvable film composition is provided to a patient.
Depending on the particular symptom sought to be treated, the film
composition may include one or more particular active components. In one
embodiment, the film composition includes a polymer carrier matrix and a
therapeutically effective amount of an agonist. Desirably the agonist is a
partial
agonist. For some types of pain, the agonist may be an opioid agonist, such as
buprenorphine or a pharmaceutically acceptable salt thereof. The film
composition
preferably includes a buffer in an amount sufficient to control the local pH
of the film
composition. Any buffer or buffering system may be used, including those
listed
above. Desirably, the local pH of the film composition including an agonist is
buffered to be about 4 to about 9, depending on the particular agonist
included in the
composition. In some embodiments, such as when the agonist is buprenorphine,
the
desired local pH is about 5 to about 6.5, and most desirably the local pH is
about 5.5
to about 6.5. At this level, the absorption of the agonist may be optimized.
To treat
the pain, the film composition is administered to the patient, most desirably
into the
oral cavity of the patient, such as through buccal absorption.
If desired, the composition may include a therapeutically effective amount of
an antagonist. As explained above, the combination of an agonist and
antagonist may
help minimize potential abuse of the agonist. The antagonist may be any
desired
antagonist, and in one embodiment includes naloxone or a pharmaceutically
acceptable salt thereof The film composition is preferably administered to
patient
through the oral cavity of the patient, but may be administered in any desired
means.
The orally dissolvable film composition is then allowed to dissolve in the
oral cavity
of the patient for a sufficient time so as to release the active(s) therein.
In some
27
embodiments, the film composition may remain in the oral cavity for at least
30
seconds, and in some embodiments may remain in the oral cavity for at least 1
minute. After the film composition is placed into the oral cavity of the
patient, the
film preferably becomes sufficiently adhered so as to render its removal
difficult.
After the film composition has been administered to the patient, the active(s)
are
sufficiently released from the composition and allowed to take effect on the
patient.
In embodiments where there is a dual-region film composition, the
administration of the dosage may have regions of differing dissolution rates.
For
example, the first region of the film composition may include an agonist and a
moderate dissolving polymer. Desirably, the first region remains in the oral
cavity for
at least one minute, and up to about 30 minutes. The second region, which may
include an antagonist, desirably contains a fast dissolving polymer. As such,
the
second region dissolves within less than one minute, thereby releasing the
antagonist
into the body where it is ingested and ionized. In this way, the antagonist is
swallowed, thereby avoiding buccal absorption. However, the antagonist is
still
present in the film composition before administration so as to limit potential
abuse of
the drug should a user attempt to extract the agonist from the composition.
The film compositions of the present invention may be formed via any desired
process. Suitable processes are set forth in U.S. Patent Nos. 7,425,292 and
7,357,891.
In one embodiment, the film dosage composition is formed by first preparing a
wet
composition, the wet composition including a polymeric carrier matrix, a
therapeutically effective amount of an agonist, and a buffer in an amount
sufficient to
control the local pH of the composition to a desired level. The wet
composition is
cast into a film and then sufficiently dried to form a self-supporting film
composition.
The wet composition may be cast into individual dosages, or it may be cast
into a
sheet, where the sheet is then cut into individual dosages. The agonist may be
a
partial agonist. If desired, the wet composition may include a therapeutically
effective amount of an antagonist. In some embodiments, especially in single-
region
dosages, the local pH of the film may be about 2 to about 4, and more
particularly
between about 3 to about 4.
The agonist and the optional antagonist are preferably selected to treat a
particular problem, such as treatment of physical pain suffered by a patient.
For
example, the agonist may include buprenorphine or a pharmaceutically
acceptable salt
28
CA 2771089 2017-11-16
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
thereof, while the antagonist may include naloxone or a pharmaceutically
acceptable
salt thereof. The film composition includes at least one buffer or buffering
system so
as to control the local pH of the agonist and antagonist to desired levels. In
this
fashion, the absorption of the agonist may be optimized while the absorption
of the
antagonist may be inhibited. In one desired embodiment, the inventive film
provides
an absorption of the agonist that is bioequivalent to that of a Suboxone
tablet.
If the desired optimum absorption of the agonist is to provide a bioequivalent
absorption to that of a Suboxone0 tablet, the local pH of the film composition
should
provide a local pH of the agonist of either between about 3 to about 4 or
between
about 5.5 to about 6.5, and a local pH of the antagonist of between about 2 to
about 4.
In a film composition including only one region with the agonist and
antagonist, the
local pH is desirably about 3 to about 4 to provide a bioequivalent absorption
to the
Suboxone0 tablet.
EXAMPLES
Example 1 ¨ Composition of Buprenorphine/Naloxone Films at Various Strengths
Film strips including a combination of buprenorphine and naloxone were
prepared. Four different strength film compositions were prepared, which
include a
ratio of buprenorphine to naloxone of 16/4, 12/3, 8/2, and 2/0.5. The
compositions
are summarized in Table 1 below.
Table 1 ¨ Various Compositions of Film Dosages
Components Buprenorphine/Naloxone Films
Unit Formula (mg per film strip)
Buprenorphine/Naloxone Ratios 16/4 12/3 8/2 2/0.5
Active Components
Buprenorphine HC1 17.28 12.96 8.64 2.16
Naloxone HC1Dihydrate 4.88 3.66 2.44 0.61
Inactive Components
Polyethylene Oxide, NF 27.09 20.32 13.55 --
(MW 200,000)
Polyethylene Oxide, NF 12.04 9.03 6.02 19.06
(MW 100,000)
Polyethylene Oxide, NF 4.82 3.62 2.41 2.05
29
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
(MW 900,000)
Maltitol, NF 12.04 9.03 6.02 5.87
Flavor 6.0 4.5 3.0 2.4
Citric Acid, USP 5.92 4.44 2.96 2.96
HPMC 4.22 3.16 2.11 2.34
Acc-K 3.0 2.25 1.5 1.2
Sodium Citrate, anhydrous 2.68 2.01 1.34 1.34
Colorant 0.03 0.02 0.01 0.01
Total (mg) 100 75 50 40
Example 2 - Absorption studies for Suboxone tablets
Various film and tablet products were prepared and tested for absorption data,
including Cmax and AUC absorption levels. The products tested included
Suboxone tablets made with either 2 mg or 16 mg buprenorphine as well as
either
0.5 mg or 4.0 mg naloxone. For 16 mg buprenorphine tablets, two 8 mg
buprenorphine tablets were combined together to provide the level of
components of a
16 mg buprenorphine tablet. In instances where a 12 mg buprenorphine tablet
was
evaluated, this dosage was obtained by combining one 8 mg buprenorphine tablet
and
two 2 mg buprenorphine tablets. These products were tested for absorption
levels,
with the amounts listed in Table 2 below.
Table 2 - Absorption Data for Suboxone products
Sample C max AUC
Buprenorphine (2 mg) Suboxone Tablet 0.780 ng/ml 6.789 heng/m1
Naloxone (0.5 mg) Suboxone Tablet 51.30 pg/m1 128.60 hr*pg/m1
Buprenorphine (16 mg) Suboxone 4.51 ng/ml 44.99 heng/m1
Tablet
Naloxone (4 mg) Suboxone Tablet 259.00 pg/ml 649.60 hr*pg/m1
Using the data from Table 2, absorption data for the Suboxone tablets for
other levels of buprenorphine and naloxone are set forth in Table 2A below.
Table 2A -Absorption Data for Suboxone tablets
Sample C max AUC
Buprenorphine (4 mg) Suboxone Tablet 1.35 ng/ml 12.25 heng/m1
Naloxone (1 mg) Suboxone Tablet 80.97 pg/m1 203 hr*pg/m1
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Buprenorphine (8 mg) Suboxone Tablet 2.29 ng/ml 23.17 heng/m1
Naloxone (2 mg) Suboxone Tablet 140.31 pg/ml
351.8 hr*pg/m1
Buprenorphine (12 mg) Suboxone 3.23 ng/ml 34.08 heng/m1
Tablet
Naloxone (3 mg) Suboxone Tablet 199.7 pg/m1 500.6
hr*pg/m1
Example 3 ¨ Evaluation of Bioequivalence of Suboxone Tablets
Using the data generated for Suboxone tablets in Table 2 above, acceptable
bioequivalence ranges are generated so as to provide an equivalent treatment
level as
the SuboxoneCR) tablet. As currently understood, a product provides a
bioequivalent
effect if it provides absorption levels between about 80% to about 125% of the
Suboxone tablet. Absorption in this range is considered to be bioequivalent.
Table 3 - Acceptable Bioequivalence Ranges for Suboxone Tablets (80 to 125%)
Description of Sample C max AUC
Buprenorphine 2 mg 0.624 to 0.975 ng/ml 5.431 to
8.486 heng/m1
Naloxone 0.5 mg 41.04 to 64.13 pg/ml 102.88 to 160.75 hr*pg/m1
Buprenorphine 16 mg 3.608 to 5.638 ng/ml 35.992 to 56.238 heng/m1
Naloxone 4 mg 207.20 to 323.75 pg/m1 519.68 to 812.00 hr*pg/m1
Thus, to be considered bioequivalent to the Suboxone tablet, the Cmax of
buprenorphine is between about 0.624 and 5.638, and the AUC of buprenorphine
is
between about 5.431 to about 56.238. Similarly, to be considered bioequivalent
to the
Suboxone(R) tablet, the Cmax of naloxone is between about 41.04 to about
323.75, and
the AUC of naloxone is between about 102.88 to about 812.00.
Example 4 ¨ Composition of Buprenorphine Films at Various Strengths
Film strips including a buprenorphine were prepared. Two different strength
film compositions were prepared, which include buprenorphine in a dosage
amount of
8 mg and in a dosage amount of 2 mg. The compositions are summarized in Table
4
below.
Table 4 ¨ Various Compositions of Film Dosages
Components Buprenorphine Films
Unit Formula (mg per film strip)
31
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Buprenorphine 8.64 2.16
Inactive Components
Polyethylene Oxide, NF 17.66 21.87
(MW 100,000)
Polyethylene Oxide, NF 2.17 2.35
(MW 900,000)
Maltitol, NF 5.43 6.72
Flavor 2.8 2.8
HPMC 1.9 2.69
Ace-K 1.2 1.2
Colorant 0.2 0.2
Total (mg) 40 40
Example 5 ¨ Cmax and AUCinf Levels for Film Strips Incorporating Buprenorphine
Five film dosage compositions were prepared, each including buprenorphine
in a dosage of from 2 mg to 16 mg. Table 5 below sets forth Cmax and AUCinf
levels for various dosage levels of film compositions including buprenorphine.
Table 5 ¨ Cmax and AUCinf Levels for Film Strips
Incorporating Buprenorphine
Buprenorphine Cmax AUCinf
2 mg 0.7 ¨ 1.07 ng/ml 6.8 ¨ 9.5 hr.ng/m1
4 mg 1.2-1.84 ng/m1 11.2-16.7 hr.ng/m1
8 mg 2.3-3.8 ng/ml 22.7-34.1 hr.ng/m1
12 mg 2.8-5.2 ng/m1 30.4-48.6 hr.ng/rn1
16 mg 4.08-6.4 ng/ml 42.6-65.8 hr.ng/m1
Example 6 ¨ Preparation of Films For In Vivo Study
Film dosages were prepared for use in an in vivo study to determine the
bioavailability of buprenorphineinaloxone tablets and film formulations.
Specifically,
the films were tested to determine whether the film provides a bioequivalent
effect to
that of a tablet formulation.
Three film formulations including 8 mg buprenorphine and 2 mg naloxone
were prepared, each being buffered to a different pH. The first film did not
include
any buffer, providing a local pH of about 6.5. The second was buffered to a
local pH
32
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
level of about 3-3.5. The third was buffered to a local pH value of about 5-
5.5. The
formulations are set forth in Table 6 below.
Table 6 - Formulations of Test Films at Various pH Levels
Component Test formulation 1 Test formulation 2 Test formulation 3
8 mg/2 mg 8 mg/2 mg 8 mg/2 mg
pH = 6.5 pH = 3-3.5 pH = 5-5.5
%w/w Mg/film %w/w Mg/film %w/w Mg/film
Buprenorphine 21.61 8.64 17.28 8.64 17.28 8.64
HC1
Naloxone HC1 6.10 2.44 4.88 2.44 4.88 2.44
Dihydrate
Polymer 5.05 2.02 4.82 2.41 4.82 2.41
Polymer 28.48 11.39 27.09 13.55 27.09 13.55
Polymer 12.65 5.06 12.04 6.02 12.04 6.02
Polymer 4.43 1.77 4.22 2.11 4.22 2.11
Sweetener 12.65 5.06 12.04 6.02 12.04 6.02
Sweetener 3 1.2 3 1.5 3 1.5
Flavor 6 2.4 6 3 6 3
Citric acid 0 0 5.92 2.96 2.51 1.26
Sodium citrate 0 0 2.68 1.34 6.08 3.04
FD&C yellow 0.025 0.01 0.03 0.02 0.03 0.02
#6
Total 100 40 100 50 100 50
Example 7 - Analysis of In Vivo Absorption of Film Having a pH of 6.5
The film dosage composition of film having a local pH of 6.5 was analyzed.
Specifically, Test Formulation 1, as prepared in Example 5 was analyzed in
vivo to
determine the absorption of buprenorphine and of naloxone. The comparative
film
was compared to the absorption of buprenorphine and of naloxone provided by a
one
dose tablet (Suboxone ). The test film was compared to determine whether it
provided a bioequivalent effect as the Suboxone tablet.
The results for Test Formulation 1, which had a local pH of about 6.5, as
compared to the one dose tablet, are set forth in Tables 7 and 8 below.
Table 7 - Buprenorphine In Vivo Absorption Data for Test Formulation 1
Suboxone sublingual Test Formulation 1
(pH = 6.5)
Parameter n Mean SD CV% n Mean SD CV%
T. (hr) 15 1.60 0.47 29.41 15 1.50 0.62 41.23
C..õ
15 2.27 0.562 24.77 15 2.60 0.872 33.53
(ng/mL)
AUCIact 15 27.08 10.40 38.41 15 31.00 12.93
41.72
33
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
(hr*ng/mL)
AUC,õf
15 29.58 11.15 37.68 15 33.37 13.88
41.61
(hr*ng/mL)
T1/2 (hr) 15 44.76 20.86 46.60 15 40.73 14.93
36.66
Table 8 - Naloxone In Vivo Absorption Data for Test Formulation 1
Suboxoneg sublingual Test Formulation 1
(pH = 6.5)
Parameter n Mean SD CV% n Mean SD CV%
Tõ,a, (hr) 15 0.90 0.23 25.32 15 0.68 0.18 25.75
C.õ
15 94.6 39.1 41.33 15 410 122 29.75
(pg/mL)
AUCIast 15 297.1 120.7 40.62 15 914.8 158.1
17.29
(hr*pg/mL)
15 306.1 122.6 40.06 15 924.2 158.8
17.18
(hr*pg/mL)
T112 (hr) 15 6.62 2.60 39.26 15 6.86 2.08 30.27
As can be seen, the in vivo data indicates that buprenorphine is absorbed very
well from the film formulation at a local pH of 6.5, and matched closely the
absorption seen in the Suboxone0 one dose tablet. However, the absorption was
also
maximized for the naloxone, which was undesirable. It was determined that a
film
having a combination of buprenorphine and naloxone and a local pH of 6.5 did
not
provide a bioequivalent effect as the one dose Suboxonet tablet for both
buprenorphine and naloxone.
Example 8 - Analysis of In Vivo Absorption of Film Having a pH of 5-5.5
Having determined the absorption of buprenorphine and naloxone in film
having a local pH of 6.5, a film dosage composition of film having a local pH
of 5-5.5
was analyzed. Specifically, Test Formulation 3, as prepared in Example 5 was
analyzed in vivo to determine the absorption of buprenorphine and of naloxone.
The
comparative films were compared to the absorption of buprenorphine and of
naloxone
provided by a one dose tablet (Suboxone0). The test film was compared to
determine
whether it provided a bioequivalent effect as the tablet product.
The results for Test Formulation 3, which had a local pH of about 5-5.5, as
compared to the one dose tablet, are set forth in Tables 9 and 10 below.
Table 9 - Buprenorphine In Vivo Absorption Data for Test Formulation 3
Suboxoneg sublingual Test Formulation 3
(pH = 5-5.5)
34
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Parameter n Mean SD CV% n Mean SD CV%
Tmax (hr) 15 1.60 0.47 29.41 14 1.50 0.43 28.50
C.
15 2.27 0.562 24.77 14 3.47 1.57 45.40
(ng/mL)
AUCIast 15 27.08 10.40 38.41 14 33.25 16.01
48.16
(hr*ng/mL)
AUCinf
15 29.58 11.15 37.68 13 38.34 15.38
40.13
(hr*ng/mL)
T112 (hr) 15 44.76 20.86 46.60 13 41.71 17.70
42.42
Table 10 - Naloxone In Vivo Absorption Data for Test Formulation 3
Suboxone sublingual Test Formulation 3
(pH = 5-5.5)
Parameter n Mean SD CV% n Mean SD CV%
T. (hr) 15 0.90 0.23 25.32 14 0.98 0.62 63.51
CmaX 15 94.6 39.1 41.33 14 173 84.5 48.79
(pg/mL)
AUChist 15 297.1 120.7 40.62 14 455.2 195.5 42.94
(hr*pg/mL)
AUCinf
(hr*pg/mL) 15 306.1 122.6 40.06 13 474.4 203.1 42.81
T112 (hr) 15 6.62 2.60 39.26 13 9.45 6.90 73.00
As can be seen, the in vivo data indicated that the absorption of
buprenorphine
increased as the local pH level decreased. It appeared that by decreasing the
local pH
from 6.5 to 5.5, the absorption of buprenorphine was being moved to a level
much
greater than that of the one dose Suboxonet tablet. In addition, the naloxone
values
did not provide a bioequivalent result as the one dose tablet. Thus, it was
determined
that the film having a local pH of 5.5 did not provide a bioequivalent result
as that of
the Suboxone0 tablet for both buprenorphine and naloxone.
It was noted that by reducing the local pH of the film to a level of 5.5,
there
would be provided an increased level of absorption of buprenorphine. Thus, it
may be
desirable to buffer a film composition incorporating buprenorphine itself to a
level of
about 5.5 to provide an increased absorption.
Example 9 - Analysis of In Vivo Absorption of Film Having a pH of 3-3.5
Having determined the absorption of buprenorphine and naloxone in films
having a local pH of 6.5 and 5.5, a film dosage composition of film having a
local pH
of about 3-3.5 was analyzed. It was assumed that the absorption of
buprenorphine
would continue to be increased as it had demonstrated at a local pH of 5.5.
Thus, it
was assumed that at a local pH of 3.5, the film would not be bioequivalent to
that of
the tablet.
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Specifically, Test Formulation 2, as prepared in Example 5, was analyzed in
vivo to determine the absorption of buprenorphine and of naloxone. The
comparative
films were compared to the absorption of buprenorphine and of naloxone
provided by
a one dose tablet (Suboxone49. The test film was compared to determine whether
it
provided a bioequivalent effect as the tablet product.
The results for Test Formulation 2, which had a local pH of about 3-3.5, as
compared to the one dose tablet, are set forth in Tables 11 and 12 below.
Table 11 - Buprenorphine In Vivo Absorption Data for Test Formulation 2
Suboxoneg sublingual Test Formulation 2
(pH = 3-3.5)
Parameter n Mean SD CV% n Mean SD CV%
TInax (hr) 15 1.60 0.47 29.41 14 1.68 0.58 34.68
C.õ 15 2.27 0.562
24.77 14 2.68 0.910 33.99
(ng/mL)
AUCIast 15 27.08 10.40 38.41 14 29.73 12.05
40.54
(hr*ng/mL)
AUCinf
29.58 11.15 37.68 14 31.45 12.98 41.26
(hr*ng/mL)
T1/2 (hr) 15 44.76 20.86 46.60 14 30.03 13.95
46.46
Table 12 - Naloxone In Vivo Absorption Data for Test Formulation 2
Suboxoneg sublingual Test Formulation 2
(pH = 3-3.5)
Parameter n Mean SD CV% n Mean SD CV%
TInax (hr) 15 0.90 0.23 25.32 14 0.84 0.19 22.19
C.õ
15 94.6 39.1 41.33 14 130 72.9 56.04
(pg/mL)
AUCIast 15 297.1 120.7 40.62 14 362.2 155.9
43.03
(hr*pg/mL)
AUCinf
15 306.1 122.6 40.06 12 350.4 142.3
40.61
(hr*pg/mL)
T112 (hr) 15 6.62 2.60 39.26 12 8.07 4.75 58.84
15 As can be seen, the in vivo data indicated that the absorption of
buprenorphine
was substantially bioequivalent to that of the one dose tablet when the film
composition local pH was lowered to about 3-3.5. This result was surprising as
it did
not appear to follow the pH partition theory. Further, at a local pH of about
3-3.5, it
was seen that the absorption of naloxone was substantially bioequivalent to
that of the
one dose tablet.
Thus, it was determined that the film product including buprenorphine and
naloxone at a local pH of 3-3.5 was substantially bioequivalent to that of the
36
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Suboxone one dose tablet. It was therefore evident that one could formulate
the
naloxone at a local pH of 3.5 or lower to inhibit its absorption, and
formulate the
buprenorphine at a local pH of about 5.5 to optimize its absorption.
Example 10 - Normalized Values for Naloxone in Films and Tablets
Various film compositions including buprenorphine and naloxone in 8/2 mg
and 2/0.5 mg dosages, and having different local pH values from 6.5 to 3.5,
were
prepared and analyzed. The data was normalized and compared to the one dose
Suboxone tablet. The results are set forth in Table 13 below.
Table 13 - Normalized Values for Naloxone Film Compared to Tablet
pH Dose (mg) AUC Cmax Mg Ratio Citric
(Normalized) Citric Acid
Buprenorphine/ Acid (mg)/Naloxone
Naloxone (mg)
6.5 8/2 3.02 4.33 1.34 0.67
5.5 8/2 1.55 1.83 1.34 0.67
3.5 8/2 1.14 1.37 1.34 0.67
3.5 2/0.5 0.98 0.90 1.34 2.68
5.5 2/0.5 1.41 1.41 1.34 2.68
The data indicates that not only is the local pH of significant importance,
but
the amount of acid present in the formula is also important. The improvement
from
the 8/2 dose to the 2/0.5 dose (at a local pH of 3.5) demonstrates this
importance. The
8/2 dose has a ratio of acid/naloxone of 0.67, and this dose provided
borderline
acceptable bioequivalent results. In contrast, the 2/0.5 dose has a ratio of
acid/naloxone of 2.68 at a local pH of 3.5, and provides a more bioequivalent
absorption value than the 8/2 dose.
In fact, the data shows that the 2/0.5 dose at a local pH of 3.5 had an even
lower buccal absorption than the one dose tablet, as seen from the normalized
values
for the AUC and Cmax. This demonstrates that even less absorption of the
naloxone
occurs for the film formulation at a local pH of 3.5 than the tablet
formulation. Given
the goal of reducing the absorption of naloxone, it appears that the film
product
buffered at a local pH of 3.5 with a buffer ratio (buffer/naloxone) of 2.68
provides
even better results than the Suboxone formulation.
37
CA 02771089 2012-02-06
WO 2011/017484
PCT/US2010/044490
Example 11 ¨Absorption Data for Dual-Film Dosage at local pH 3.5 and local pH
5.5
A dual-film dosage is prepared, with the first film layer having a local pH of
about 3.5 and containing an antagonist therein, and the second film layer
having a
local pH of about 5.5 and containing an agonist therein. In this dual-film
dosage, the
first film layer (having the antagonist) is a fast-dissolving film, while the
second film
layer (having the agonist) is a moderate dissolving film. Using data from the
above
studies, absorption levels for various amounts of product in the film is
presented in
Table 14 below:
Table 14 ¨ Extrapolated Absorption Data for Dual-Layered
Film at Agonist Local pH of 3.5 and Naloxone Local pH of 5.5
Dose Naloxone Naloxone AUC
(mg agonist! Cmax (pg/ml) (hr*pg/m1)
mg naloxone)
2/0.5 32.5 90.5
8/2 130 362
16/4 260 724
Therefore, at amounts of 0.5-4.0 mg, the Cmax level for the Naloxone is
between about 32.5 to about 260 pg/ml and the AUC for the Naloxone is between
about 90.5 to about 724 hr*pg/ml. As will be understood, varying types and
levels of
buffers may increase or decrease the absorption values. That is, when seeking
to
inhibit the absorption of the antagonist (i.e., naloxone), one may select a
particular
local pH for the agonist region and a second local pH for the antagonist
region. The
local pH of the region may depend on the amount of active included in that
region.
The amounts of actives incorporated into the dosage may be altered to provide
suitable absorption levels, and may include amounts in milligrams, nanograms,
picograms, or any desired amount of active.
38
